Tivicay

The exact ViiV human product, strengths and current official labels are transparent and authorised in major human-medicine jurisdictions. The assessed feline oral FIV use has no veterinary authorisation, feline oral dossier or formulation-specific target-animal evidence; the species, route and regimen mismatch limits regulatory and scientific applicability.

The only direct feline study treated six experimentally infected cats with subcutaneous dolutegravir plus tenofovir and emtricitabine. Selected haematological and immunophenotypic findings improved, but blood and saliva viraemia did not fall significantly; the study cannot isolate dolutegravir, oral delivery or this tablet, and no natural-infection clinical outcome study establishes benefit.

Extensive human labelling and the small 18-week feline combination experiment provide limited safety context, not an oral feline safety profile. Oral exposure, chronic toxicity, resistance selection, reproductive safety, organ-disease effects and interaction magnitude in cats remain unvalidated, so a favourable safety judgment is not supported.

The 10 mg tablet is the lowest whole-tablet strength and therefore the least impractical of the three, but no validated feline oral dose, PK bridge, tablet division/crushing instruction or treatment schedule exists. It cannot yet support an actionable prescription.

The exact ViiV human product, strengths and current official labels are transparent and authorised in major human-medicine jurisdictions. The assessed feline oral FIV use has no veterinary authorisation, feline oral dossier or formulation-specific target-animal evidence; the species, route and regimen mismatch limits regulatory and scientific applicability.

The only direct feline study treated six experimentally infected cats with subcutaneous dolutegravir plus tenofovir and emtricitabine. Selected haematological and immunophenotypic findings improved, but blood and saliva viraemia did not fall significantly; the study cannot isolate dolutegravir, oral delivery or this tablet, and no natural-infection clinical outcome study establishes benefit.

Extensive human labelling and the small 18-week feline combination experiment provide limited safety context, not an oral feline safety profile. Oral exposure, chronic toxicity, resistance selection, reproductive safety, organ-disease effects and interaction magnitude in cats remain unvalidated, so a favourable safety judgment is not supported.

The whole-only 25 mg tablet adds a substantial dose-unit precision problem for a cat, on top of the absent feline oral dose, PK bridge and treatment schedule. Unvalidated splitting or crushed-powder estimation would not make the regimen reliable.

The exact ViiV human product, strengths and current official labels are transparent and authorised in major human-medicine jurisdictions. The assessed feline oral FIV use has no veterinary authorisation, feline oral dossier or formulation-specific target-animal evidence; the species, route and regimen mismatch limits regulatory and scientific applicability.

The only direct feline study treated six experimentally infected cats with subcutaneous dolutegravir plus tenofovir and emtricitabine. Selected haematological and immunophenotypic findings improved, but blood and saliva viraemia did not fall significantly; the study cannot isolate dolutegravir, oral delivery or this tablet, and no natural-infection clinical outcome study establishes benefit.

Extensive human labelling and the small 18-week feline combination experiment provide limited safety context, not an oral feline safety profile. Oral exposure, chronic toxicity, resistance selection, reproductive safety, organ-disease effects and interaction magnitude in cats remain unvalidated, so a favourable safety judgment is not supported.

The whole-only 50 mg tablet has the greatest dose-unit mismatch for a cat, while no feline oral dose, PK bridge or treatment schedule exists. It is the least practical presentation and must not be converted from the experimental SC figure.